For Physicians. By Physicians.™
For Physicians. By Physicians.™
This study by Eggebroten et al. (AJOG, 2017) aimed to evaluate the insertion, expulsion, and 6-month continuation of immediate postpartum copper T380 intrauterine devises (IUDs), levonorgestrel IUDs, and contraceptive implants.
Prospective Observational Trial
350 women had an IUD or implant inserted immediately after delivery, and enrolled in a 6-month follow-up. 27% received copper IUDs, 38% received levonorgestrel IUDs, and 35% received implants, with most women (93%) receiving their contraception of choice. 90% of participants were Hispanic, 87% were multiparous, 87% reported a household income of <$24,000 a year, and 77% delivered vaginally. 89% of the women completed the 6-month follow-up. 17% of levonorgestrel IUD users reported expulsions, compared to 4% of copper IUD users, with an adjusted hazard ratio for expulsion was 5.8 (confidence interval, 1.3-26.4). Mode of delivery did not affect expulsion rates. 14 of the 21 women who experienced IUD expulsions requested a LARC replacement. The 6 month device continuation rate was ≥80% among all device types. Levonorgestrel IUDs had higher expulsion rates than the copper IUD, but both had high success rates. The authors conclude that an immediate postpartum LARC program is highly effective and provides women with a convenient way to receive their contraception of choice before leaving the hospital.
Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis
Please log in to ObGFirst to access the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
